An overview of nonalcoholic steatohepatitis: past, present and future directions.
about
Therapeutic targets in the ASK1-dependent stress signaling pathwaysInsulin signaling regulates fatty acid catabolism at the level of CoA activationPrevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma.Glucose transporter 8 (GLUT8) mediates fructose-induced de novo lipogenesis and macrosteatosis.Serum gamma glutamyl transferase and alanine transaminase concentrations predict endothelial dysfunction in patients with non-alcoholic steatohepatitis.Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet.Specific inhibition of the redox activity of ape1/ref-1 by e3330 blocks tnf-α-induced activation of IL-8 production in liver cancer cell linesEvaluation of carotid intima-media thickness and flow-mediated dilatation in middle-aged patients with nonalcoholic fatty liver diseaseElevated serum transaminase activities were associated with increased serum levels of iron regulatory hormone hepcidin and hyperferritinemia risk.Evaluation of relationship between grading of fatty liver and severity of atherosclerotic finding.Associations between Serum Uric Acid and the Remission of Non-Alcoholic Fatty Liver Disease in Chinese MalesApplication of polyunsaturated fatty acids in internal medicine: beyond the established cardiovascular effects.Experimental Nonalcoholic Steatohepatitis Induced by Neonatal Streptozotocin Injection and a High-Fat Diet in Rats.Problems and possible solutions for therapy with statins.Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statementHepatic and serum lipid signatures specific to nonalcoholic steatohepatitis in murine models.Comparative Study on the Effect of Plantago psyllium and Ocimum basilicum Seeds on Anthropometric Measures in Nonalcoholic Fatty Liver Patients.Downregulation of sulfotransferase expression and activity in diseased human livers.Cdc2-like kinase 2 suppresses hepatic fatty acid oxidation and ketogenesis through disruption of the PGC-1α and MED1 complex.Antifibrotic effects of ambrisentan, an endothelin-A receptor antagonist, in a non-alcoholic steatohepatitis mouse model.Arginase 2 deficiency results in spontaneous steatohepatitis: a novel link between innate immune activation and hepatic de novo lipogenesis.
P2860
Q26999030-A7C29413-D548-4765-8009-FDADB341D179Q27334898-D814377E-436A-4776-99F5-CBAD30A46D76Q33554179-B2805ADA-AE10-460D-A088-8271E3D22021Q33676162-236A1006-5FBD-4818-BE91-4E41CD3B5AE0Q34311151-AC2C7E74-B529-4EE8-A7F4-4845B2B1C718Q34796362-10CE679D-DC79-40E4-AE6C-77A7873F0B5EQ34963206-13AB3E30-1DC5-449B-AEA6-65D2BB8E9EB6Q35576708-DFF88342-DA47-4B62-80F9-AF2E4B2018A7Q35972918-1A6FDEA6-64E2-4DEE-B3E2-39AD90B51FAAQ36111640-D88A93DE-66A2-4375-A75E-1DBFF90A2B01Q36189821-DA020D5B-C57C-4AFE-925D-D2838F5C1295Q36423040-32A2B58B-999A-40A8-B49A-4D5FA8A02DC4Q36528723-EB0309D9-E127-4A81-BFD6-8F823A669E7CQ37007848-B2DA75DD-376D-44CE-82F8-7F3EA39F9877Q37037106-335AF9AD-4200-4BEE-B5AC-07659BD0E2F2Q37166770-B323185E-5246-4CC5-9C67-19B8371E8152Q37349823-6CD0CFED-288E-464D-A1E3-B9D1BFCCF833Q37422741-230F9A17-98F6-47C3-A867-31D76CF527D8Q37715596-764B6FA5-0783-4B3B-9A75-C247FCD97146Q41986030-54DC26F3-83F3-415B-AFAA-A8E07F841BDFQ42111412-43D2E790-9C2D-4837-A36C-E1F7C40D65E3
P2860
An overview of nonalcoholic steatohepatitis: past, present and future directions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
An overview of nonalcoholic steatohepatitis: past, present and future directions.
@en
An overview of nonalcoholic steatohepatitis: past, present and future directions.
@nl
type
label
An overview of nonalcoholic steatohepatitis: past, present and future directions.
@en
An overview of nonalcoholic steatohepatitis: past, present and future directions.
@nl
prefLabel
An overview of nonalcoholic steatohepatitis: past, present and future directions.
@en
An overview of nonalcoholic steatohepatitis: past, present and future directions.
@nl
P2093
P1476
An overview of nonalcoholic steatohepatitis: past, present and future directions.
@en
P2093
Alina Pascale
Raluca Pais
Vlad Ratziu
P304
P577
2010-12-01T00:00:00Z